An easy way to do this is to go to Settings & privacy > Content preferences, and then open the “Unfollow people and groups” ...

Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

Instagram is rolling out a new update that addresses a long-standing frustration among users. The Reels algorithm is finally becoming more transparent and customizable. Users can now manually select ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

Children as young as 4 years old are capable of finding efficient solutions to complex problems, such as independently inventing sorting algorithms developed by computer scientists. The scientists ...

A new report out today from network security company Tenable Holdings Inc. details three significant flaws that were found in Google LLC’s Gemini artificial intelligence suite that highlight the risks ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...